MRI Surveillance Alone Benefits Cognitive Function in Small-Cell Lung Cancer Patients

A significant advancement in the management of small-cell lung cancer (SCLC) has been observed through results of the SWOG S1827 MAVERICK phase III trial. The study, recently discussed at the IASLC 2026 World Conference on Lung Cancer, demonstrated that regular brain MRI surveillance without the addition of prophylactic cranial irradiation (PCI) notably preserves cognitive function while still maintaining comparable overall survival rates.

Led by Dr. Chad Rusthoven from the University of Colorado, the trial revealed that patients subjected to brain MRI surveillance alone experienced a significant improvement in cognitive failure-free survival. These findings were consistent across patients with both limited and extensive-stage SCLC, supporting MRI surveillance as a potentially new standard of care.

Historically, PCI has been emphasized to reduce the incidence of brain metastases in SCLC due to its previously noted survival benefits before the widespread adoption of MRI. However, PCI is often linked with neurocognitive side effects, leading to a reconsideration of its use, especially in the context of advanced imaging techniques like MRI.

The MAVERICK trial involved 304 participants with SCLC who had no detectable brain metastases post-initial treatment and were divided to undergo either MRI surveillance alone or MRI combined with PCI. MRI was scheduled quarterly in the first year and biannually in the second year, accompanied by standardized cognitive tests. Notably, 68% of participants were classified with limited-stage disease.

After a median follow-up of 22 months, MRI-alone surveillance showed a marked advantage in cognitive failure-free survival (hazard ratio, 0.60; 90% CI, 0.46–0.78; P=0.0005), a benefit observed consistently regardless of disease stage or immunotherapy use. While progression-free survival did not vary significantly between groups, an early look at overall survival following 128 deaths indicated no substantial difference (hazard ratio for MRI alone, 0.90; 90% CI, 0.67–1.20).

This trial emphasizes the increasing viability of deploying MRI surveillance over traditional PCI for patients with SCLC, underlining the importance of cognitive health alongside oncological outcomes. As the final overall survival analysis is anticipated following 190 deaths, these preliminary results offer crucial insights for clinical guidelines.